



शरीरग्राथ खलु धर्मसाधनम्

# Polycystic ovary syndrome:

## The pros and cons of various diagnostic criteria and biomarkers

*Ashutosh Halder*

MD, DNB, DM, MRCOG I, Common. Sch. (Fetal Med), FAMS

Professor & Head

Department of Reproductive Biology

AIIMS, New Delhi

# PCOS: Original Description

**Stein IF and Leventhal ML.**  
**Amenorrhea associated with**  
**bilateral polycystic ovaries.**  
**Am J Obstet Gynecol 1935;**  
**29:181-191.**

Oral presentation at a meeting of the Central Association of Obstetricians and Gynecologists, **Nov. 1-3, 1934**

7 cases (5 amenorrhoeic & 2 irregular cycles); 5 conceived after wedge resection



**Stein**

1. Secondary amenorrhea/ irregular periods and sterility
2. Bilateral and symmetrically enlarged ovaries
3. Normal amounts of **17-KS** and **FSH** in urine (exclude CAH & POF)

About 50 percent of patients, there was a varying degree of hirsutism. The breasts were smaller than normal in 50%, and uterine hypoplasia in 75%



**Leventhal**


# PCOS: Diagnostic Criteria

revised in 2016; AMH may be used in place of USG

| NIH 1990                                                                                                                                                                                                                                                 | Rotterdam 2003                                                                                                                                                                                                            | AE-PCOS Society 2006                                                                                                                                                                                                                   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>• Chronic anovulation</li> <li>• Clinical and/or biochemical signs of hyperandrogenism (with exclusion of other etiologies, e.g., congenital adrenal hyperplasia)</li> </ul> <p><i>(Both criteria needed)</i></p> | <ul style="list-style-type: none"> <li>• Oligo- and/or anovulation</li> <li>• Clinical and/or biochemical signs of hyperandrogenism</li> <li>• Polycystic ovaries</li> </ul> <p><i>(Two of three criteria needed)</i></p> | <ul style="list-style-type: none"> <li>• Clinical and/or biochemical signs of hyperandrogenism</li> <li>• Ovarian dysfunction (Oligo-anovulation and/or polycystic ovarian morphology)</li> </ul> <p><i>(Both criteria needed)</i></p> |

1990 NIH consensus

2003 Rotterdam consensus



NIH: Prevalence~10%    AES: Prevalence~12%    Rot: Prevalence~15%

# Definitions related to PCOS

## Oligomenorrhoea or amenorrhoea

Oligomenorrhoea: menstrual cycle length >35/45 to 182 days)

Amenorrhoea: no menstruation for >182 days

with normal FSH & E2

## Hyperandrogenism (HA): Clinical &/or Biochemical

*Clinical HA:*

for hirsutism assessment Ferriman-Gallwey score  $\geq 9$

*Biochemical HA:*



FAI >4.5/high T (>0.6 ng/ml)

## Poly Cystic Ovaries (PCO) &/or Enlarged Ovaries (EO)

Ovaries >10 ml (one or both)

Follicles size 2-9 mm and count  $\geq 12$  (one or both ovaries)

FAI: total testosterone (nmol/l; 1ng/dl = 0.0347 nmol/l) divided by the SHBG (nmol/l), and then multiplying 100



**Ferriman-Gallwey score ( $\geq 9$ )**

# Our study (n=153)

after exclusion of secondary causes

- Total no. of cases referred as PCOS (suspected) 258
- No. of cases fulfils Rotterdam criteria 153
- No. of cases fulfils AES/AES+ criteria 124/128
- No. of cases fulfils NIH criteria 114
- No. of cases fulfils all 3 criteria 068
- No. of cases fulfils SLS criteria 097

Work-up: BMI, FGS, total testosterone, LH, FSH, AMH, Inhibin B, DHEAS, 17-OH P, cortisol, insulin (F), BS (F), prolactin, TSH, E2, P4, etc (FAI in few, chromosome in specific cases, etc)

# PCOS: NIH criteria do not consider PCO/EO

- Polycystic ovarian morphology or enlarged ovary: not necessary to diagnose the syndrome  
(PCO/EO term coined by Stein and Leventhal)
- Need to **assign a new name** if continued to follow this diagnostic criteria

What is appropriate name?

**oligomenorrhoea/amenorrhoea due to hyperandrogenism (HA)**

**Clinical HA/Hirsutism: good marker but Biochemical HA is a bad marker in our study**

**Missing large number of cases compared Rotterdam criteria (n=39)**

**Cases without HA are many (n=29)**

## AES criteria (revised in 2016)

- **Clinical Hyperandrogenism** (Ferriman-Gallwey score  $\geq 9$ ) or **Biochemical Hyperandrogenism** (FAI  $>4.5$ /high Testosterone  $>0.6$  ng/ml)

- **Oligomeno/amenorrhea** (chronic anovulation) **or**
- **Polycystic Ovary** ( $>24$  follicles on USG/8MHz probe)

**or Enlarged Ovary** (each ovarian volume  $>12$  ml/10 ml in case low resolution probe)

**or**

**AMH** ( $>10$  ng/ml definite or  $>7$  ng/ml likely or  $>5$  ng/ml may be)

**Missing large number of cases compared to Amsterdam criteria (n=29)**

**Cases without HA (n=29) going to be missed**



# Summary

| Parameters         | Oligo/<br>Amenn | FGS<br>>8 | PCO/EO<br>on USG | High<br>Testo<br>>0.6<br>ng/ml | AMH<br>>7/>5<br>ng/ml | LH/FSH<br>>2 | High<br>Inhibin B<br>>100<br>pg/ml | High<br>DHEAS<br>>450<br>ug/dl | BMMI<br>high/low<br>>25/<18 |
|--------------------|-----------------|-----------|------------------|--------------------------------|-----------------------|--------------|------------------------------------|--------------------------------|-----------------------------|
| Rotterd<br>(n=153) | 93.5%           | 78%       | 81.7%            | 26.5%                          | 61/<br>78%            | 24.7%        | 30.3%                              | 3.6%                           | 50.9%<br>/3.9%              |
| AES<br>(n=124)     | 92%             | 94.3%     | 76.4%            | 32.5%                          | 61/<br>78%            | 25.4%        | 31%                                | 3.5%                           | 53%<br>/4%                  |
| NIH<br>(n=114)     | 100%            | 93.8%     | 73.9%            | 32.7%                          | 60.9/<br>79%          | 25.9%        | 31.9%                              | 2.8%                           | 54.4%<br>/4.4%              |
| SLS<br>(n=97)      | 100%            | 65.6%     | 100%             | 24.7%                          | 62.2/<br>81%          | 29%          | 33.9%                              | 3.4%                           | <b>45.3%</b><br><b>/4%</b>  |
| All 3<br>(n=67)    | 100%            | 94%       | 100%             | 35.4%                          | 65.6/<br>85%          | 32.8%        | 29.2%                              | 3.2%                           | 46.2%<br>/4.4%              |

*Similar specificity/sensitivity (after exclusion of CAH & other secondary causes)*

# Summary (cont.)

| Parameters      | Cortisol high<br>>20 ug/dl | Cortisol low<br><3.5 ug/dl | 17-OH P4 high<br>>3 ng/ml | Insulin high<br>>25 miu/ml |
|-----------------|----------------------------|----------------------------|---------------------------|----------------------------|
| Rotterd (n=153) | 2.2%                       | 2.2%                       | 11.5%                     | 7.2%                       |
| AES (n=124)     | 2.7%                       | 2.7%                       | 11.5%                     | 7%                         |
| NIH (n=114)     | 2%                         | 2%                         | 11.2%                     | 6.7%                       |
| SLS (n=97)      | 1.2%                       | 2.3%                       | 14.3%                     | 5.7%                       |
| All 3 (n=67)    | 1.7%                       | 3.4%                       | 15.5%                     | 4.9%                       |

*Similar specificity/sensitivity (after exclusion of CAH & other secondary causes)*

# Secondary cause of PCOS (suspected)

| Am/olig       | PCO/EO      | FGS >8    | T          | 17-OHP        | Corti      | DHE-AS      | AMH         | FSH       | LH  | E2/P4         | PCO criter    | Prov Diag           |
|---------------|-------------|-----------|------------|---------------|------------|-------------|-------------|-----------|-----|---------------|---------------|---------------------|
| <b>Pri Am</b> | Normal      | <b>21</b> | <b>2.8</b> | <b>&gt;20</b> | 5.5        | <b>1024</b> | 3.3         | 3.2       | 0.9 | 49/ 0.5       | NIH, AES, RDC | <b>CAH comp.</b>    |
| <b>Pri Am</b> | Not visible | <b>30</b> | <b>2.3</b> | 0.4           | 15         | 164         | <b>0.3</b>  | <b>35</b> | 13  | <b>18/xx</b>  | NIH, AES, RDC | <b>XY DSD 5ARD</b>  |
| <b>olig</b>   | <b>yes</b>  | <b>9</b>  | <b>1.2</b> | <b>9.1</b>    | <b>2.1</b> | 164         | <b>0.16</b> | 4.3       | 9.8 | 114/0.2       | <b>all</b>    | <b>CAH non-c</b>    |
| <b>olig</b>   | <b>yes</b>  | 8         | 0.4        | <b>0.2</b>    | <b>5</b>   | <b>123</b>  | 11.2        | 5.5       | 5.6 | <b>0.2/66</b> | RDC SLC       | <b>CAH ?17 OH D</b> |
| <b>olig</b>   | Normal      | <b>10</b> | 0.3        | 1.1           | 8          | 170         | <b>0.19</b> | <b>21</b> | 5.5 | <b>12/0.2</b> | NIH, AES, RDC | <b>Ov Ins</b>       |
| <b>olig</b>   | <b>yes</b>  | 4         | <b>0.8</b> | <b>8.9</b>    | <b>23</b>  | <b>788</b>  | 11.8        | 3.3       | 2.2 | 30/0.7        | <b>all</b>    | <b>Adren hyper</b>  |

*None criteria seems differentiate primary to secondary PCOS, although SLC relatively better in excluding most*



18 yrs; BMI **25.8** ( $n < 25$ )  
**Primary amenorrhea**  
**FG score 14 & T 1.48** ( $n < 0.6$ )  
**USG msf & enlarged ovary**  
(17, 18 ml),  
**AMH >25** ng/ml  
LH/FSH ratio **2.1** ( $n < 2$ )  
Cortisol **5.5** ug/dl ( $n > 3.7$ )  
17-OH P **2.4** ng/ml ( $n < 3$ )  
Insulin (F) **15** uIU/ml ( $n < 20$ )  
DHEAS **144** ug/dl ( $n < 550$ )  
E2 **80** pg/ml ( $n > 20$  efp)  
P **0.3** ng/ml  
PRL **6.5** ng/ml ( $n < 28$ )  
FSH **2.06** mIU/ml ( $n 1-8$ )

PCOS as per **all criteria** (NIH/AES/Rot/SLC)

PCOS



Age: 16+ yrs  
 Pr Amenorrhea  
 FGS 21; T 2.8 (<0.6 ng/ml)  
 USG: normal  
 AMH 3.28 ng/ml  
 DHEAS 1123 (<550 ug/dl)  
 17-OHP >200 ng/ml  
 Cortisol 5.58 (3.5-20) compensated  
 LH/FSH <1 (FSH 3.2)  
 PRL 30 ng/ml; E2 78.2 pg/dl  
 Insulin 7.4 uiu/ml  
 Ch. 46,XX; BP 140/90

PCOS as per NIH/AES/Rot, but **X SLS criteria**

**CAH (compensated)**



20 years; reared as girl  
**Primary amenorrhoea**  
**FGS 30, T 2.3**  
**USG-no ov/ut**  
**Excess hair growth, change in voice, body habitus & behavi, clitoromegally, etc**  
**AMH 0.3; LH-13, FSH-35**  
**17-OHP-0.4, cortisol 15, DHEAS-164,**  
**Inhibin B-3.8, E2-18**  
**Ch 46,XY; SRY +ve, AZF +ve**  
**PCOS:NIH,AES,RDC; X SLC**  
**46,XY DSD (?5ARD)**

# Observation

- Oligomenorrhoea/amenorrhoea: observed in >90% (10-15% cases amenorrhoea; maximum with NIH & minimum with SLC)
- Clinical HA: Ferriman-Gallwey score of >8 observed in 65-90% cases (minimum in SLC & maximum in AES/NIH)

Features like hair fall, acne, voice change, etc are frequent but less reliable (need guideline to include in work-up)

- Biochemical HA: FAI >4.5 in very few cases; high total testosterone in only 25% (SLC) - 35% (AES) cases
- Adrenal dysfunction (mild/atypical CAH or hypercorticism) is common (10-20% cases) but difficult to exclude; 17-hydroxylase deficiency exist
- AMH >7 in 60%/>5 in 80% (not conclusive, 40% <7/20% <5)
- DHEAS (<4%) or LH/FSH ratio (~25%) are poor markers
- Insulin resistance/hyperinsulinemia in only 5-7% cases
- BMI>25 in 50% (45% in SLC/55% in AES) & <18 in 4% cases

# Conclusion

- **We should follow Rotterdam criteria which at present detects most cases of PCOS (if facility to exclude secondary causes exist) as this is most sensitive and as specific as NIH/AES criteria in north Indian PCOS cases**  
**Secondary causes are adrenal dysfunction (hypo/ hyper), ovarian insufficiency, gonadal dysgenesis/DSD, etc (USG, LH, FSH, AMH, T, 17-OH P, cortisol, DHEAS, prolactin, TSH, E2/P4, chromosome, etc)**
- **Otherwise we should follow SLC criteria as it has ability to exclude most secondary causes (↑specific but ↓sensitive)**
- **AMH value of 7 (>60%) or >5 (80%) is better biomarker than T, LH/FSH, DHEAS, 17-OH P & Inhibin B (4-25%)**

**About 9/6% suspected PCOS cases (not fitting any criteria) had >5/7 AMH**



Thank you

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**

Jointly Organized by  
The PCOS Society (India) &  
The Androgen Excess & PCOS Society (International)  
Dates: June 16 - 18, 2017 Bengaluru

Jointly Organized by  
The PCOS Society (India) &  
The Androgen Excess & PCOS Society (International)  
Dates: June 16 - 18, 2017 Bengaluru

Jointly Organized by  
The PCOS Society (India) &  
The Androgen Excess & PCOS Society (International)  
Dates: June 16 - 18, 2017 Bengaluru

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**  
Jointly Organized by  
The PCOS Society (India) &  
The Androgen Excess & PCOS Society (International)  
Dates: June 16 - 18, 2017 Bengaluru

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**  
Organized by  
The PCOS Society (India) &  
The Androgen Excess & PCOS Society (International)  
Dates: June 16 - 18, 2017 Bengaluru

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**  
Jointly Organized by  
The PCOS Society (India) &  
The Androgen Excess & PCOS Society (International)  
Dates: June 16 - 18, 2017 Bengaluru

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**  
Jointly Organized by  
The PCOS Society (India) &  
The Androgen Excess & PCOS Society (International)  
Dates: June 16 - 18, 2017 Bengaluru

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**  
Jointly Organized by  
The PCOS Society (India) &  
The Androgen Excess & PCOS Society (International)  
Dates: June 16 - 18, 2017 Bengaluru

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**  
Jointly Organized by  
The PCOS Society (India) &  
The Androgen Excess & PCOS Society (International)  
Dates: June 16 - 18, 2017 Bengaluru

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**

THE INTERNATIONAL CONFERENCE  
**PCOS - UNRAVELING THE ENIGMA**